In today's economic landscape, where inflation and rising interest rates are a constant concern, companies are compelled to prioritize efficiency and cash flow management. This focus is essential not ...
Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at ...
In the study, a once-daily, single-tablet combination of bictegravir and lenacapavir was as effective as Gilead's existing ...
By Dana PiccoliNEWS IS OUT The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to ...
Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. It is the first work ...
Clinical Trials Arena on MSN
Gilead’s HIV ART combo deemed non-inferior in second phase III trial
Gilead Sciences’ human immunodeficiency virus (HIV) single-tablet combination antiretroviral therapy (ART) has proven ...
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback